{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:29:38Z","timestamp":1792718978715,"version":"4.5.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.mam.2010.04.001","type":"journal-article","created":{"date-parts":[[2010,5,7]],"date-time":"2010-05-07T08:54:24Z","timestamp":1273222464000},"page":"287-329","source":"Crossref","is-referenced-by-count":73,"title":["Signal transduction therapy of cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Alexander","family":"Levitzki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.mam.2010.04.001_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.addr.2007.03.010","article-title":"Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity","volume":"59","author":"Akhtar","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.mam.2010.04.001_bib2","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI33494","article-title":"Nonviral delivery of synthetic siRNAs in vivo","volume":"117","author":"Akhtar","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-07-2182","article-title":"Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3","volume":"68","author":"Amann","year":"2008","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/CJI.0b013e3181a1c097","article-title":"Antitumor activity of an EpCAM\/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release","volume":"32","author":"Amann","year":"2009","journal-title":"J. Immunother."},{"issue":"7","key":"10.1016\/j.mam.2010.04.001_bib5","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1016\/S0021-9258(18)42864-5","article-title":"Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins","volume":"267","author":"Anafi","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.mam.2010.04.001_bib7","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1182\/blood.V82.12.3524.3524","article-title":"Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate","volume":"82","author":"Anafi","year":"1993","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mam.2010.04.001_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/BJ20080728","article-title":"Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations","volume":"415","author":"Avizienyte","year":"2008","journal-title":"Biochem. J."},{"issue":"3\u20134","key":"10.1016\/j.mam.2010.04.001_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000151362","article-title":"Targeting Her-2\/neu in breast cancer: as easy as this!","volume":"74","author":"Azim","year":"2008","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.mam.2010.04.001_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem. J."},{"issue":"5891","key":"10.1016\/j.mam.2010.04.001_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"Pt 2","key":"10.1016\/j.mam.2010.04.001_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1042\/BJ20041140","article-title":"Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors","volume":"385","author":"Barnett","year":"2005","journal-title":"Biochem. J."},{"issue":"52","key":"10.1016\/j.mam.2010.04.001_bib13","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.mam.2010.04.001_bib14","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1158\/0008-5472.CAN-05-3827","article-title":"Genetically engineered models have advantages over xenografts for preclinical studies","volume":"66","author":"Becher","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2010.04.001_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0065-230X(05)94002-5","article-title":"Activation of AKT kinases in cancer: implications for therapeutic targeting","volume":"94","author":"Bellacosa","year":"2005","journal-title":"Adv. Cancer Res."},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/embo-reports\/kvf094","article-title":"ROS, stress-activated kinases and stress signaling in cancer","volume":"3","author":"Benhar","year":"2002","journal-title":"EMBO Rep."},{"issue":"Suppl. 6","key":"10.1016\/j.mam.2010.04.001_bib17","doi-asserted-by":"crossref","first-page":"vi26","DOI":"10.1093\/annonc\/mdm220","article-title":"Lapatinib in breast cancer","volume":"18","author":"Bilancia","year":"2007","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib18","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1124\/mol.104.002758","article-title":"Designing transcription factor architectures for drug discovery","volume":"66","author":"Blancafort","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/157489208783478702","article-title":"Inhibitors of chronically active ras: potential for treatment of human malignancies","volume":"3","author":"Blum","year":"2008","journal-title":"Recent Pat. Anticancer Drug. Discov."},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.mam.2010.04.001_bib21","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1021\/cr000250y","article-title":"Chemical inhibitors of protein kinases","volume":"101","author":"Bridges","year":"2001","journal-title":"Chem. Rev."},{"issue":"8","key":"10.1016\/j.mam.2010.04.001_bib22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT 110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol. Immunol."},{"issue":"20","key":"10.1016\/j.mam.2010.04.001_bib23","doi-asserted-by":"crossref","first-page":"8322","DOI":"10.1158\/0008-5472.CAN-07-6720","article-title":"Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors","volume":"68","author":"Buck","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.mam.2010.04.001_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0065-230X(08)00004-3","article-title":"Molecular mechanisms and therapeutic development of angiogenesis inhibitors","volume":"100","author":"Cao","year":"2008","journal-title":"Adv. Cancer Res."},{"issue":"7152","key":"10.1016\/j.mam.2010.04.001_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the pleckstrin homology domain of AKT 1 in cancer","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.mam.2010.04.001_bib26","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1101\/gad.1025302","article-title":"Inhibition of Hedgehog signaling by direct binding of cyclopamine to smoothened","volume":"16","author":"Chen","year":"2002","journal-title":"Genes Dev."},{"issue":"20","key":"10.1016\/j.mam.2010.04.001_bib27","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1158\/1078-0432.CCR-07-4879","article-title":"The type 1 insulin-like growth factor receptor pathway","volume":"14","author":"Chitnis","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.mam.2010.04.001_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1750-3639.2009.00318.x","article-title":"EGFRvIII-targeted vaccination therapy of malignant glioma","volume":"19","author":"Choi","year":"2009","journal-title":"Brain Pathol."},{"issue":"46","key":"10.1016\/j.mam.2010.04.001_bib29","doi-asserted-by":"crossref","first-page":"19467","DOI":"10.1073\/pnas.0911436106","article-title":"Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists","volume":"106","author":"Chung","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7287","key":"10.1016\/j.mam.2010.04.001_bib30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/464358a","article-title":"Drug discovery: inhibitors that activate","volume":"464","author":"Cichowski","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/BJ20091428","article-title":"Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation","volume":"425","author":"Cohen","year":"2009","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","article-title":"PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment","volume":"15","author":"Crawford","year":"2009","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.mam.2010.04.001_bib33","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2007.15.0672","article-title":"Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (invite): a randomized, phase II study","volume":"26","author":"Crino","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.mam.2010.04.001_bib34","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrg2634","article-title":"Causes and consequences of microRNA dysregulation in cancer","volume":"10","author":"Croce","year":"2009","journal-title":"Nat. Rev. Genet."},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib35","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/0008-5472.CAN-08-2627","article-title":"Characterization of a novel mitogen-activated protein kinase kinase 1\/2 inhibitor with a unique mechanism of action for cancer therapy","volume":"69","author":"Daouti","year":"2009","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.mam.2010.04.001_bib36","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2002.02.126","article-title":"Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma","volume":"20","author":"Dillman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting ras signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.mam.2010.04.001_bib38","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.mam.2010.04.001_bib39","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.mam.2010.04.001_bib40","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nmeth1079","article-title":"MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells","volume":"4","author":"Ebert","year":"2007","journal-title":"Nat. Methods"},{"issue":"7189","key":"10.1016\/j.mam.2010.04.001_bib41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in non-human primates","volume":"452","author":"Elmen","year":"2008","journal-title":"Nature"},{"issue":"5827","key":"10.1016\/j.mam.2010.04.001_bib42","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"7240","key":"10.1016\/j.mam.2010.04.001_bib43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.mam.2010.04.001_bib44","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1634\/stemcells.2007-1073","article-title":"Brain cancer stem cells display preferential sensitivity to Akt inhibition","volume":"26","author":"Eyler","year":"2008","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib45","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ejca.2004.01.009","article-title":"Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery","volume":"40","author":"Fiebig","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib46","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/sj.bjc.6602428","article-title":"Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors","volume":"92","author":"Fischel","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.mam.2010.04.001_bib47","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11912-008-0040-9","article-title":"The future of tyrosine kinase inhibitors: single agent or combination?","volume":"10","author":"Flaherty","year":"2008","journal-title":"Curr. Oncol. Rep."},{"issue":"12","key":"10.1016\/j.mam.2010.04.001_bib48","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/sj.onc.1208437","article-title":"A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT 3 in prostate cancer cells","volume":"24","author":"Flowers","year":"2005","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.mam.2010.04.001_bib49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.mam.2010.04.001_bib50","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.steroids.2008.10.014","article-title":"Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways","volume":"74","author":"Fox","year":"2009","journal-title":"Steroids"},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib51","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/sj.mt.6300162","article-title":"Prostate cancer gene therapy clinical trials","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.mam.2010.04.001_bib52","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.1371\/journal.pone.0001574","article-title":"Anomalous features of EMT during keratinocyte transformation","volume":"3","author":"Geiger","year":"2008","journal-title":"PLoS One"},{"issue":"Suppl. 10","key":"10.1016\/j.mam.2010.04.001_bib53","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.transproceed.2008.10.017","article-title":"The impact of mTOR inhibitors on the development of malignancy","volume":"40","author":"Geissler","year":"2008","journal-title":"Transplant. Proc."},{"issue":"37","key":"10.1016\/j.mam.2010.04.001_bib54","doi-asserted-by":"crossref","first-page":"27020","DOI":"10.1074\/jbc.M701108200","article-title":"Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3\/6-independent and -dependent mechanisms","volume":"282","author":"Gills","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.mam.2010.04.001_bib55","first-page":"2609","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins","volume":"118","author":"Guix","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"5644","key":"10.1016\/j.mam.2010.04.001_bib56","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"issue":"31","key":"10.1016\/j.mam.2010.04.001_bib57","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1200\/JCO.2005.01.8234","article-title":"Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2010.04.001_bib58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12015-008-9021-5","article-title":"Glioma formation, cancer stem cells, and akt signaling","volume":"4","author":"Hambardzumyan","year":"2008","journal-title":"Stem Cell Rev."},{"issue":"7148","key":"10.1016\/j.mam.2010.04.001_bib59","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nature05939","article-title":"A microRNA component of the p53 tumour suppressor network","volume":"447","author":"He","year":"2007","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib60","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ccr.2009.10.015","article-title":"The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors","volume":"16","author":"Hedvat","year":"2009","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib61","first-page":"76","article-title":"Dual targeting of epigenetic therapy in cancer","volume":"1775","author":"Hellebrekers","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.mam.2010.04.001_bib62","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/156800908786733450","article-title":"Anti-angiogenic targets in the treatment of advanced renal cell carcinoma","volume":"8","author":"Heng","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nbt1366","article-title":"Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo","volume":"26","author":"Henke","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib64","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ccr.2007.10.028","article-title":"p53 enters the microRNA world","volume":"12","author":"Hermeking","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib65","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib66","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nantod.2009.07.001","article-title":"Molecular imaging and therapy of cancer with radiolabeled nanoparticles","volume":"4","author":"Hong","year":"2009","journal-title":"Nano Today"},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib67","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.humpath.2007.03.001","article-title":"The role of KIT in the management of patients with gastrointestinal stromal tumors","volume":"38","author":"Hornick","year":"2007","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib68","first-page":"2166","article-title":"Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis","volume":"6","author":"Huang","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2013 mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"5706","key":"10.1016\/j.mam.2010.04.001_bib70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"issue":"7182","key":"10.1016\/j.mam.2010.04.001_bib71","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nature06607","article-title":"Regulation of progenitor cell proliferation and granulocyte function by microRNA-223","volume":"451","author":"Johnnidis","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.mam.2010.04.001_bib72","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","article-title":"Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials","volume":"84","author":"Johnson","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.mam.2010.04.001_bib73","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"9652","key":"10.1016\/j.mam.2010.04.001_bib75","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib76","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrc2545","article-title":"Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer","volume":"9","author":"Kirn","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mam.2010.04.001_bib77","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0065-230X(06)97013-4","article-title":"Targeted cancer therapy: promise and reality","volume":"97","author":"Klein","year":"2007","journal-title":"Adv. Cancer Res."},{"issue":"2","key":"10.1016\/j.mam.2010.04.001_bib78","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ceb.2008.12.006","article-title":"Targeting the EGFR and the PKB pathway in cancer","volume":"21","author":"Klein","year":"2009","journal-title":"Curr. Opin. Cell Biol."},{"issue":"7","key":"10.1016\/j.mam.2010.04.001_bib79","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc1651","article-title":"Killing time for cancer cells","volume":"5","author":"Klein","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"5517","key":"10.1016\/j.mam.2010.04.001_bib80","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.mam.2010.04.001_bib81","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1182\/blood-2005-02-0553","article-title":"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy","volume":"106","author":"Kojima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.mam.2010.04.001_bib82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv. Immunol."},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib83","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","article-title":"Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model","volume":"137","author":"Kota","year":"2009","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib84","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol. Cell"},{"issue":"17","key":"10.1016\/j.mam.2010.04.001_bib85","doi-asserted-by":"crossref","first-page":"11717","DOI":"10.1074\/jbc.M900217200","article-title":"Shift from apoptotic to necrotic cell death during human papillomavirus-induced transformation of keratinocytes","volume":"284","author":"Kravchenko-Balasha","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00063030-200923010-00001","article-title":"Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies","volume":"23","author":"Kreitman","year":"2009","journal-title":"BioDrugs"},{"issue":"1\u20133","key":"10.1016\/j.mam.2010.04.001_bib87","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2009.10.011","article-title":"Epigenetics and cancer treatment","volume":"625","author":"Kristensen","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.mam.2010.04.001_bib88","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1039\/b708320c","article-title":"Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy","volume":"6","author":"Kuimova","year":"2007","journal-title":"Photochem. Photobiol. Sci."},{"issue":"8","key":"10.1016\/j.mam.2010.04.001_bib89","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1200\/JCO.2008.17.8251","article-title":"Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms","volume":"27","author":"Lai","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2010.04.001_bib90","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12033-009-9161-0","article-title":"Cancer detection and treatment: the role of nanomedicines","volume":"42","author":"LaRocque","year":"2009","journal-title":"Mol. Biotechnol."},{"issue":"20","key":"10.1016\/j.mam.2010.04.001_bib91","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1158\/1078-0432.CCR-05-0849","article-title":"Topotecan combination chemotherapy in two new rodent models of retinoblastoma","volume":"11","author":"Laurie","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib92","first-page":"57","article-title":"Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination","volume":"12","author":"Lee","year":"2003","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"14","key":"10.1016\/j.mam.2010.04.001_bib93","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","article-title":"A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy","volume":"68","author":"Lee-Hoeflich","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib94","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1535-6108(03)00334-9","article-title":"Small-molecule antagonists of the oncogenic Tcf\/beta-catenin protein complex","volume":"5","author":"Lepourcelet","year":"2004","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.mam.2010.04.001_bib95","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1096\/fasebj.6.14.1426765","article-title":"Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction","volume":"6","author":"Levitzki","year":"1992","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-1033.1994.tb20020.x","article-title":"Signal-transduction therapy. A novel approach to disease management","volume":"226","author":"Levitzki","year":"1994","journal-title":"Eur. J. Biochem."},{"issue":"5205","key":"10.1016\/j.mam.2010.04.001_bib97","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1126\/science.7892601","article-title":"Tyrosine kinase inhibition: an approach to drug development","volume":"267","author":"Levitzki","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.mam.2010.04.001_bib98","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.biochem.75.103004.142657","article-title":"Tyrphostins and other tyrosine kinase inhibitors","volume":"75","author":"Levitzki","year":"2006","journal-title":"Annu. Rev. Biochem."},{"issue":"22","key":"10.1016\/j.mam.2010.04.001_bib99","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody\u2013cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"issue":"1\u20133","key":"10.1016\/j.mam.2010.04.001_bib100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"16","key":"10.1016\/j.mam.2010.04.001_bib101","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1021\/bi061928s","article-title":"A novel substrate mimetic inhibitor of PKB\/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway","volume":"46","author":"Litman","year":"2007","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib102","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/1078-0432.329.11.1","article-title":"Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice","volume":"11","author":"Liu","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5186","key":"10.1016\/j.mam.2010.04.001_bib103","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.7973635","article-title":"p53 status and the efficacy of cancer therapy in vivo","volume":"266","author":"Lowe","year":"1994","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib104","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1021\/bi034515p","article-title":"Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition","volume":"43","author":"Luo","year":"2004","journal-title":"Biochemistry"},{"issue":"15","key":"10.1016\/j.mam.2010.04.001_bib105","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.mam.2010.04.001_bib106","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1517\/14712590903348135","article-title":"Denileukin diftitox: a novel immunotoxin","volume":"9","author":"Manoukian","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"issue":"7","key":"10.1016\/j.mam.2010.04.001_bib107","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","article-title":"Modeling the therapeutic efficacy of p53 restoration in tumors","volume":"127","author":"Martins","year":"2006","journal-title":"Cell"},{"issue":"6566","key":"10.1016\/j.mam.2010.04.001_bib108","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/379645a0","article-title":"Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor","volume":"379","author":"Meydan","year":"1996","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.mam.2010.04.001_bib109","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1021\/jm0580196","article-title":"High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors","volume":"48","author":"Mishani","year":"2005","journal-title":"J. Med. Chem."},{"issue":"7270","key":"10.1016\/j.mam.2010.04.001_bib110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature08543","article-title":"Direct inhibition of the NOTCH transcription factor complex","volume":"462","author":"Moellering","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.mam.2010.04.001_bib111","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1017\/S1462399409001215","article-title":"Antibody-based therapy of leukaemia","volume":"11","author":"Morris","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"issue":"2","key":"10.1016\/j.mam.2010.04.001_bib112","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.coi.2009.02.004","article-title":"Adoptive immunotherapy of cancer using CD4(+) T cells","volume":"21","author":"Muranski","year":"2009","journal-title":"Curr. Opin. Immunol."},{"issue":"20","key":"10.1016\/j.mam.2010.04.001_bib113","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/1078-0432.CCR-09-0209","article-title":"Therapy-induced PML\/RARA proteolysis and acute promyelocytic leukemia cure","volume":"15","author":"Nasr","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"29","key":"10.1016\/j.mam.2010.04.001_bib114","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1200\/JCO.2005.05.5335","article-title":"Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer","volume":"24","author":"Nemunaitis","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2010.04.001_bib115","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib116","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"O\u2019Shea","year":"2004","journal-title":"Cancer Cell"},{"issue":"7042","key":"10.1016\/j.mam.2010.04.001_bib117","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.mam.2010.04.001_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(01)80010-5","article-title":"Involvement of platelet-derived growth factor in disease: development of specific antagonists","volume":"80","author":"Ostman","year":"2001","journal-title":"Adv. Cancer Res."},{"issue":"7","key":"10.1016\/j.mam.2010.04.001_bib119","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mam.2010.04.001_bib120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-065X.2008.00649.x","article-title":"Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy","volume":"224","author":"Peggs","year":"2008","journal-title":"Immunol. Rev."},{"issue":"7","key":"10.1016\/j.mam.2010.04.001_bib121","first-page":"1829","article-title":"Antibody to HER-2\/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells","volume":"9","author":"Pietras","year":"1994","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.mam.2010.04.001_bib122","first-page":"1347","article-title":"Monoclonal antibody to HER-2\/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene","volume":"59","author":"Pietras","year":"1999","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.mam.2010.04.001_bib123","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0026-895X(25)10152-1","article-title":"Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program","volume":"45","author":"Posner","year":"1994","journal-title":"Mol. Pharmacol."},{"issue":"29","key":"10.1016\/j.mam.2010.04.001_bib124","doi-asserted-by":"crossref","first-page":"20638","DOI":"10.1016\/S0021-9258(19)36734-1","article-title":"Kinetic model of the epidermal growth factor (EGF) receptor tyrosine kinase and a possible mechanism of its activation by EGF","volume":"267","author":"Posner","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"Spec. No. 1","key":"10.1016\/j.mam.2010.04.001_bib125","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1093\/hmg\/ddi115","article-title":"Epigenetic control in the immune response","volume":"14","author":"Reiner","year":"2005","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.mam.2010.04.001_bib126","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","article-title":"p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage","volume":"11","author":"Reinhardt","year":"2007","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.mam.2010.04.001_bib127","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1158\/0008-5472.CAN-07-5783","article-title":"Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity","volume":"68","author":"Rhodes","year":"2008","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.mam.2010.04.001_bib128","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf\u2013MEK\u2013ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.mam.2010.04.001_bib129","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1023\/A:1006196614142","article-title":"Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer)","volume":"17","author":"Rosenberg","year":"1998","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"10.1016\/j.mam.2010.04.001_bib130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mam.2010.04.001_bib131","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0076-6879(07)00432-6","article-title":"The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer","volume":"439","author":"Rotblat","year":"2008","journal-title":"Methods Enzymol."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib132","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/theoncologist.2007-0199","article-title":"The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer","volume":"13","author":"Ryan","year":"2008","journal-title":"Oncologist"},{"issue":"4\u20135","key":"10.1016\/j.mam.2010.04.001_bib133","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.drup.2008.07.001","article-title":"Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers","volume":"11","author":"Sabbah","year":"2008","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.mam.2010.04.001_bib134","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1215\/15228517-2008-012","article-title":"Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors","volume":"10","author":"Sampson","year":"2008","journal-title":"Neuro-oncol"},{"issue":"13","key":"10.1016\/j.mam.2010.04.001_bib135","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1158\/1078-0432.CCR-07-0588","article-title":"Cancer vaccines: moving beyond current paradigms","volume":"13","author":"Schlom","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"5 Suppl. 16","key":"10.1016\/j.mam.2010.04.001_bib136","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0093-7754(01)90278-7","article-title":"Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart","volume":"28","author":"Schneider","year":"2001","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib137","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2006.07.3585","article-title":"Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer","volume":"25","author":"Sequist","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.mam.2010.04.001_bib138","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nbt730","article-title":"Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR","volume":"20","author":"Shir","year":"2002","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.mam.2010.04.001_bib139","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1371\/journal.pmed.0030006","article-title":"EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice","volume":"3","author":"Shir","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.mam.2010.04.001_bib140","unstructured":"Shir, A., Ogris, M., Roedl, W., Wagner, E., Levitzki, A., submitted for publication. EGFR-homing dsRNA activates cancer targeted immune response and eliminates disseminated EGFR over-expressing tumors in mice."},{"issue":"5687","key":"10.1016\/j.mam.2010.04.001_bib141","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Sordella","year":"2004","journal-title":"Science"},{"issue":"7213","key":"10.1016\/j.mam.2010.04.001_bib142","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nature07260","article-title":"Modelling Myc inhibition as a cancer therapy","volume":"455","author":"Soucek","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.mam.2010.04.001_bib143","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/cmdc.200900301","article-title":"The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors","volume":"4","author":"Spannhoff","year":"2009","journal-title":"ChemMedChem"},{"issue":"Pt 6","key":"10.1016\/j.mam.2010.04.001_bib144","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1042\/BST0361197","article-title":"Targeting of microRNAs for therapeutics","volume":"36","author":"Stenvang","year":"2008","journal-title":"Biochem. Soc. Trans."},{"issue":"2","key":"10.1016\/j.mam.2010.04.001_bib145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semcancer.2008.01.004","article-title":"The utility of LNA in microRNA-based cancer diagnostics and therapeutics","volume":"18","author":"Stenvang","year":"2008","journal-title":"Semin. Cancer Biol."},{"issue":"4","key":"10.1016\/j.mam.2010.04.001_bib146","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/08916930802024616","article-title":"Epigenetics in human autoimmunity. Epigenetics in autoimmunity \u2013 DNA methylation in systemic lupus erythematosus and beyond","volume":"41","author":"Strickland","year":"2008","journal-title":"Autoimmunity"},{"issue":"7254","key":"10.1016\/j.mam.2010.04.001_bib147","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature08199","article-title":"Modulation of microRNA processing by p53","volume":"460","author":"Suzuki","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib148","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1349-7006.2006.00190.x","article-title":"Mouse models of gastrointestinal tumors","volume":"97","author":"Taketo","year":"2006","journal-title":"Cancer Sci."},{"issue":"12","key":"10.1016\/j.mam.2010.04.001_bib149","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1089\/hum.2009.163","article-title":"The current state of head and neck cancer gene therapy","volume":"20","author":"Thomas","year":"2009","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.mam.2010.04.001_bib150","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/1535-7163.MCT-07-0211","article-title":"Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT\/PKB: mechanistic involvement of AKT catalytic activation loop cysteines","volume":"6","author":"Toral-Barza","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.mam.2010.04.001_bib151","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/onc.2009.445","article-title":"Regression of murine lung tumors by the let-7 microRNA","volume":"29","author":"Trang","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.mam.2010.04.001_bib152","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1038\/onc.2009.353","article-title":"MicroRNAs as potential cancer therapeutics","volume":"27","author":"Trang","year":"2009","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.mam.2010.04.001_bib153","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/onc.2009.334","article-title":"Histone deacetylases and the immunological network: implications in cancer and inflammation","volume":"29","author":"Villagra","year":"2010","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.mam.2010.04.001_bib154","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.mam.2010.04.001_bib155","first-page":"4227","article-title":"Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models","volume":"9","author":"Voskoglou-Nomikos","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2010.04.001_bib156","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0065-2776(06)90003-0","article-title":"Development of antibodies and chimeric molecules for cancer immunotherapy","volume":"90","author":"Waldmann","year":"2006","journal-title":"Adv. Immunol."},{"issue":"5844","key":"10.1016\/j.mam.2010.04.001_bib157","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.1.5844.13","article-title":"Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels","volume":"1","author":"Ward","year":"1973","journal-title":"Br. Med. J."},{"issue":"5578","key":"10.1016\/j.mam.2010.04.001_bib158","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes \u2013 the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.mam.2010.04.001_bib159","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"19","key":"10.1016\/j.mam.2010.04.001_bib160","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.mam.2010.04.001_bib161","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","article-title":"BiTEs: bispecific antibody constructs with unique anti-tumor activity","volume":"10","author":"Wolf","year":"2005","journal-title":"Drug Discov. Today"},{"issue":"20","key":"10.1016\/j.mam.2010.04.001_bib162","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.1073\/pnas.0602468103","article-title":"A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer","volume":"103","author":"Xia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4880","key":"10.1016\/j.mam.2010.04.001_bib163","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1126\/science.3263702","article-title":"Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors","volume":"242","author":"Yaish","year":"1988","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.mam.2010.04.001_bib164","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11748-008-0433-6","article-title":"Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer","volume":"57","author":"Yasumoto","year":"2009","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"issue":"5","key":"10.1016\/j.mam.2010.04.001_bib165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10637-005-2899-8","article-title":"Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer","volume":"23","author":"Yeon","year":"2005","journal-title":"Invest. New Drugs"},{"issue":"11","key":"10.1016\/j.mam.2010.04.001_bib166","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT 3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mam.2010.04.001_bib1a","doi-asserted-by":"crossref","unstructured":"Zenvirt, S., Kravchenko-Balasha, N., Levitzki, A., 2010. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents. Oncogene, in press.","DOI":"10.1038\/onc.2010.343"},{"issue":"7280","key":"10.1016\/j.mam.2010.04.001_bib167","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299710000348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299710000348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T17:43:55Z","timestamp":1740073435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299710000348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":167,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0098299710000348"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2010.04.001","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}